You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恩華藥業(002262.SZ)收到CY150112片及TRV-130注射液兩個1類化學藥品《臨牀試驗通知書》
格隆匯 06-03 15:53

格隆匯6月3日丨恩華藥業(002262.SZ)公佈,公司於近日收到國家食品藥品監督管理局核准簽發的CY150112片及TRV-130注射液兩份1類化學藥品《臨牀試驗通知書》,並將於近期開展上述2個藥品的臨牀試驗。

對於上述兩個1類化學藥物,公司將按照藥監局核發的《臨牀試驗通知書》的要求進行臨牀試驗,待臨牀試驗成功後將申報相關產品的生產批件。上述藥品的獲批生產,將進一步豐富公司在精神類及麻醉類藥品的產品線。

鑑於臨牀試驗研究具有周期長、投入大的特點,上述藥品臨牀試驗的完成時間、進度、結果以及未來產品市場競爭形勢均存在諸多不確定性,對公司近期業績不會產生較大影響,公司將對上述藥品的後續進展情況及時履行信息披露義務,敬請廣大投資者謹慎決策,注意投資風險!

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account